These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11311292)

  • 21. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
    Muscle Study Group
    Neurology; 2008 Aug; 71(6):394-9. PubMed ID: 18434639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil.
    Termsarasab P; Katirji B
    J Neuroimmunol; 2012 Aug; 249(1-2):83-5. PubMed ID: 22613699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravenous immunoglobulins in chronic idiopathic myositis].
    Michels H; Burmester GR; Buttgereit F
    Z Rheumatol; 2005 Mar; 64(2):102-10. PubMed ID: 15793676
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
    Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
    J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Siddiqi ZA
    Ann N Y Acad Sci; 2008; 1132():249-53. PubMed ID: 18567876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Oskarsson B; Rocke DM; Dengel K; Richman DP
    Neurology; 2016 Mar; 86(12):1159-63. PubMed ID: 26850977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis].
    Wang RY; Chen H; Huang ZX; Chen Y; Zhong JM
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1034-1039. PubMed ID: 37905760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe skin reaction related to mycophenolate mofetil for myasthenia gravis.
    Levin N; Mali A; Karussis D
    Clin Neuropharmacol; 2005; 28(3):152-3. PubMed ID: 15965319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.
    Meriggioli MN; Rowin J; Richman JG; Leurgans S
    Ann N Y Acad Sci; 2003 Sep; 998():494-9. PubMed ID: 14592919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.
    Hauser RA; Malek AR; Rosen R
    Neurology; 1998 Sep; 51(3):912-3. PubMed ID: 9748061
    [No Abstract]   [Full Text] [Related]  

  • 37. Mycophenolate mofetil in dermatomyositis: is it safe?
    Rowin J; Amato AA; Deisher N; Cursio J; Meriggioli MN
    Neurology; 2006 Apr; 66(8):1245-7. PubMed ID: 16636243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressive disorder associated with mycophenolate mofetil.
    Draper HM
    Pharmacotherapy; 2008 Jan; 28(1):136-9. PubMed ID: 18154484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.
    Burns TM; Sanders DB; Kaminski HJ; Wolfe GI; Narayanaswami P; Venitz J
    Muscle Nerve; 2015 May; 51(5):635-7. PubMed ID: 25704880
    [No Abstract]   [Full Text] [Related]  

  • 40. Low-dose tacrolimus for intractable myasthenia gravis.
    Yoshikawa H; Mabuchi K; Yasukawa Y; Takamori M; Yamada M
    J Clin Neurosci; 2002 Nov; 9(6):627-8. PubMed ID: 12604270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.